Dicerna Pharmaceuticals Inc

Form 4 February 20, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** Section 16. Form 4 or

OMB

3235-0287 Number:

OMB APPROVAL

January 31, Expires: 2005 Estimated average

0.5

burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Form 5

obligations

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading Weissman James B Issuer Symbol Dicerna Pharmaceuticals Inc (Check all applicable) [DRNA] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner Other (specify X_ Officer (give title (Month/Day/Year) below) C/O DICERNA 09/24/2013 Chief Business Officer PHARMACEUTICALS, INC., 480 ARSENAL STREET, BLDG 1, **SUITE 120** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting WATERTOWN, MA 02472

(City)	(State)	Zip) Table	e I - Non-Do	erivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquir on(A) or Disposed of (Instr. 3, 4 and 5) (A) or		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/05/2013		Code V M	Amount 833	(D)	Price \$ 3.42	833	D	
Common Stock	01/27/2014		M	11,283	A	\$ 3.24	12,116	D	
Common Stock	01/29/2014		P	1,000	A	\$ 15	13,116	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: Dicerna Pharmaceuticals Inc - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour Underlying Securit (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Employee Stock Option (right to buy)	\$ 3.42	01/27/2014		М		11,216	<u>(1)</u>	09/24/2023	Common Stock	11,2
Employee Stock Option (right to buy)	\$ 3.42	01/27/2014		M		67	<u>(2)</u>	04/27/2022	Common Stock	6
Employee Stock Option (right to buy)	\$ 3.42	11/11/2013		M		733	(2)	04/27/2022	Common Stock	73
Employee Stock Option (right to buy)	\$ 3.42	11/11/2013		M		100	(3)	04/27/2022	Common Stock	10
Employee Stock Option (right to buy)	\$ 3.42	09/24/2013		A	60,000		(3)	09/24/2023	Common Stock	60,0
Employee Stock Option (right to buy)	\$ 3.42	09/24/2013		A	90,000		<u>(1)</u>	09/24/2023	Common Stock	90,0

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Weissman James B C/O DICERNA PHARMACEUTICALS, INC. 480 ARSENAL STREET, BLDG 1, SUITE 120 WATERTOWN, MA 02472			Chief Business Officer				

Signatures

/ s John Green 02/17/2014

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests 1/48 monthly on last day of each month with a vesting start date of 7/30/2013.
- (2) Vests 25% after the first year anniversary of the vesting start date of 01/01/2012 and the remaining 75% vests at 1/36 per month thereafter.
- (3) The vesting of this option is subject to achievement of pre-established performance goals.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3